Slide 1: Capital Raising Presentation December 2016
For personal use only Capital Raising Presentation December 2016 Commercial in Confidence
Slide 2: Disclaimer
// 2 DISCLAIMER This presentation does not constitute investment, legal, taxation or other advice and the For personal use only presentation does not take into account your investment objectives, financial situation or particular needs. You are responsible for forming your own opinions and conclusio
Slide 3: Investment Highlights
// 3 INVESTMENT HIGHLIGHTS • Global business targeting over $250bn market opportunity in OHS – FDA, CE Mark, TGA approved For personal use only • FY 16 revenue 2.3 times FY15: • Strong start to Q217, following record Q117 • US 1H17 revenue on track to exceed US FY16 revenue • US reimbursement suppor
Slide 4: 2016 in Review – Highlights from an Exceptional Year
2016 IN REVIEW – HIGHLIGHTS FROM AN EXCEPTIONAL YEAR // 4 1. Grew revenue from $1.35M to $3.0M, reduced expenditure by $1.4M For personal use only 2. V6 sensor development on time and budget (App based, less COGS, cross platform and fast) 3. Successful launch of OHS ViSafe product into the UK and US
Slide 5: Revenue Up 2.3 Times on Lower Cost Base
// 5 REVENUE UP 2.3 TIMES ON LOWER COST BASE For personal use only dorsaVi Customer Revenue 2013 2014 2015 2016 Q1 2017 3,000 Revenue 398,607 529,380 1,358,218 3,019,000 1,004,000* EBITDA (2,148,749) (3,852,593) (8,684,709) (5,915,567) N/A 2,500 1,008 Loss from (1,659,235) (3,562,024) (8,036,161) (5
Slide 6: Strong Global Growth
// 6 STRONG GLOBAL GROWTH dorsaVi Sales Revenue For personal use only $2.0M $1.8M $1.6M $1.4M $1.2M Q4 $1.0M Q3 Q2 $0.8M Q1 $0.6M $0.4M $0.2M $0.0M FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 AU UK US
Slide 7: Imminent Release of V6 Sensors – Game Changer
// 7 IMMINENT RELEASE OF V6 SENSORS – GAME CHANGER For personal use only
Slide 8: Market Excited by the Ease of Application
// 8 MARKET EXCITED BY THE EASE OF APPLICATION For personal use only Launch of myViSafe™ New cloud-based New cloud-based • Mini sensors clinical application for: clinical application for: • Manual Handling App • Running • Low Back • Video training • Knee • Walking • Pre employment screening • Functi
Slide 9: Successful Launch of OHS Product into US & UK
// 9 SUCCESSFUL LAUNCH OF OHS PRODUCT INTO US & UK For personal use only • Work injuries estimated to cost over $250B p.a. (US) • Large untapped market with appetite for data • Unique IP leading to reduced injuries & costs • Interventions involving: • Job assessment • Equipment change • Pre-employme
Slide 10: ViSafe in Action
// 10 ViSafe IN ACTION For personal use only Putting ‘Train Stop’ to gauge Remove ‘Train Stop’
Slide 11: Compelling Offering Leading to Annuity Revenue
// 11 COMPELLING OFFERING LEADING TO ANNUITY REVENUE For personal use only Problem for major corporates: • Lack of visibility on injuries and costs • Poor ability to understand and change issues dorsaVi offering: • ViSafe projects (real data from the field) • Provides insights, risk matrix and solut
Slide 12: Achieved Strong Growth in Clinical & Sports
// 12 ACHIEVED STRONG GROWTH IN CLINICAL & SPORTS For personal use only 10 devices in FY15 80 devices in FY16 160 devices in 25 devices added in Q1 FY17 the market 24,000 physios (0.5% penetration) 85 devices in the market 48,000 physios 105 devices in the market 284,000 physical therapists
Slide 13: Clinical Platform to Manage Data, Reports and Communication
// 13 CLINICAL PLATFORM TO MANAGE DATA, REPORTS AND COMMUNICATION For personal use only Insurer PATIENT REPORTS AND DATA $ Doctor Employer Patient Specialist Physio Hospital Live Assessment Live Training Monitoring Biofeedback Exercises Reports
Slide 14: Signed with Scale Partners in the US & UK
// 14 SIGNED WITH SCALE PARTNERS IN THE US & UK For personal use only Targeting large and company-owned franchise networks • UK – YPP • US – Relationship with Select Medical Collaborative product development • Product commercially released: ViPerform AMI
Slide 15: Launched Agent Model for Rapid Revenue Growth
// 15 LAUNCHED AGENT MODEL FOR RAPID REVENUE GROWTH For personal use only Stages of OHS ViSafe work Scalable model: • Direct sales representatives in key markets • Sales partnerships with agents (win work & provide assessors) • Insurers and Insurance Brokers • Centralised analysis
Slide 16: Existing Reimbursement Codes Supporting US Roll Out
// 16 EXISTING REIMBURSEMENT CODES SUPPORTING US ROLL OUT For personal use only • Initial target of $35 per session through existing reimbursement code 97750 • Billing multiple codes per session (Average billing >$150 per session) • Relationships building with groups like Select Medical and other gr
Slide 17: Reimbursement Strategy Progressed with Registry
// 17 REIMBURSEMENT STRATEGY PROGRESSED WITH REGISTRY For personal use only • US-based patient registry launched for low back pain to support reimbursement strategy • Low Back Registry will recruit over 1,500 US-based low back pain patients in the first 18 months • Initial 3 sites, headed by Washing
Slide 18: Commercial Pilots with World Leaders
// 18 COMMERCIAL PILOTS WITH WORLD LEADERS For personal use only • • Unique insights coming from these commercial research projects Each project will lead to multiple new publications and potential new IP 65+ RESEARCH PROJECTS • 45,000 individual data sets and building daily • Medical device and pha
Slide 19: Proposed Capital Raising
For personal use only // 19 Proposed Capital Raising
Slide 20: Capital Raising
// 20 CAPITAL RAISING • dorsaVi Ltd (dorsaVi) intends to raise A$6.0-8.0m via a Placement and Share Purchase Plan (SPP) at $0.46 For personal use only per share • $3.0-5.0m Placement to sophisticated and institutional investors under listing rule 7.1 and 7.1A • $2.0m to be subscribed for by major sh
Slide 21: Capital Raising – Indicative Timetable
// 21 CAPITAL RAISING For personal use only Indicative Timetable* Company in trading halt Friday 9th December 2016 SPP record date Monday 12th December 2016 Capital raising announced and resumption of ASX trading Tuesday 13th December 2016 Dispatch SPP offer documents to eligible shareholders Wednes
Slide 22: About dorsaVi
For personal use only About dorsaVi // 22
Slide 23: dorsaVi Timeline
WV dorsaVi | Timeline > 1995 2000 + Andrew Ronchi + Sensor prototype began contemplating development begins developing a + Theory that underpins medical device dorsaVi technology established using government grants, by Andrew and Dan Ronchi > ~ | 2004 2006 * Patent protection prototype Vorsion 3 ) J
Slide 24: Board and Senior Management
BOARD AND SENIOR MANAGEMENT // 24 For personal use only Chairman Non Executive Director Non Executive Director Non Executive Director Herb Elliott Greg Tweedly Michael Panaccio Ash Attia Director & CEO Andrew Ronchi CFO CIO CPO CMO Head of Sales and Head of Sales and Head of Sales and Damian Connell
Slide 25: Our Business: Solid Foundation for Growth
// 25 OUR BUSINESS: SOLID FOUNDATION FOR GROWTH For personal use only • Three key business divisions with diversified revenue streams • Organisational health and safety • Clinical • Elite sports • Market leader with first mover advantage • Patent protected technology • Significant barriers to entry
Slide 26: The Hardware and Products
// 26 THE HARDWARE AND PRODUCTS For personal use only • OHS solution to determine, measure and mitigate high risk activities • Patent protected movement algorithms • Significant appetite for innovative manual handling solutions on medical-grade sensor technology • Executive and board-level focus on
Slide 27: For personal use only
of y Allianz @ e6l bhpbilliton \WWorktvell & MONASH ~~ University Hiscpor moc] RRB FREMANTLE +
Slide 28: dorsaVi contact details
// 28 dorsaVi™ For personal use only Andrew Ronchi PhD (Eng), B.App.Sci (Physio) Chief Executive Officer Level 1, 120 Jolimont Road, East Melbourne, Victoria 3002 Office: +61 9652 2192 | Mobile: +61 417 882 267 ar@dorsaVi.com | dorsaVi.com